Exchange Traded Concepts’s Viking Therapeutics VKTX Stock Holding History

Exchange Traded Concepts’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.17M	Sell	81,186 -2,383	-3%	-$77K	0.01%	579
2026 Q1	$2.72M	Buy	83,569 +28,004	+50%	+$900K	0.02%	525
2025 Q4	$1.95M	Sell	55,565 -3,699	-6%	-$131K	0.01%	596
2025 Q3	$1.56M	Buy	59,264 +5,750	+11%	+$172K	0.01%	632
2025 Q2	$1.42M	Buy	53,514 +20,296	+61%	+$534K	0.02%	568
2025 Q1	$802K	Sell	33,218 -1,291	-4%	-$40.8K	0.01%	661
2024 Q4	$1.39M	Sell	34,509 -34,994	-50%	-$2M	0.03%	473
2024 Q3	$4.4M	Buy	69,503 +52,968	+320%	+$3.11M	0.1%	185
2024 Q2	$877K	Buy	+16,535	New	+$1.08M	0.02%	478

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Exchange Traded Concepts's VKTX Position: Q2 2026 in Review

Exchange Traded Concepts reduced its Viking Therapeutics (VKTX) stake by 2.9% in Q2 2026, selling an estimated $77K and leaving 81,186 shares worth $3.17M. The position accounts for 0.01% of the portfolio, ranked #579.

Exchange Traded Concepts first reported a position in VKTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.4M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Exchange Traded Concepts held 81,186 shares of Viking Therapeutics worth $3.17M as of Q2 2026.
Exchange Traded Concepts sold 2,383 Viking Therapeutics shares in Q2 2026, an estimated $77K.
Viking Therapeutics made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #579 holding.
Exchange Traded Concepts first reported a position in Viking Therapeutics in Q2 2024 and has held it in 9 quarters since.
Exchange Traded Concepts's Viking Therapeutics position peaked at $4.4M in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.